Search results for "prostate"

showing 10 items of 621 documents

Characterization of the metabolic profile and identification of potential therapeutic targets in advanced prostate cancer patients

2023

INTRODUCCIÓN El cáncer de próstata (CaP) representa el segundo tumor en incidencia en hombres y es la quinta causa de muerte por cáncer a nivel global. El CaP es un tumor hormono-dependiente, que requiere de la activación del receptor de andrógenos (AR) para su proliferación. Clínicamente, se caracteriza por una gran variabilidad en su evolución, progresando desde una condición indolente hasta un fenotipo agresivo que puede diseminarse y metastatizar a los nodos linfáticos y huesos. Actualmente, el diagnóstico temprano del CaP se realiza mediante la determinación sérica del antígeno prostático específico (PSA) y el examen rectal digital (DRE). Si estas pruebas dan resultados anómalos y hay …

resonancia magnética nuclearesencialidad génicacáncer de próstatatherapeutic targetbiomarkersUNESCO::CIENCIAS TECNOLÓGICASprostate cancerdianas terapéuticasmetabolomicsnuclear magnetic resonancebiomarcadoresgene essentialityUNESCO::CIENCIAS MÉDICASmetabolómica
researchProduct

Abstract 1423: Shikonin impairs the growth of docetaxel-resistant prostate cancer cells by necroptosis

2021

Abstract Introduction: Prostate carcinoma (PCa) is the most common malignancy in men. Androgen-targeted therapy and chemotherapy are currently the treatment of choice for advanced stages. Due to resistance towards these therapies, prognosis remains poor and new treatment options are urgently required. Shikonin (SHI) from Traditional Chinese Medicine (TCM) might be promising, since it induces anti-tumor effects in different tumor entities. However, data on PCa are few, and data on resistant PCa are not existent. Material and Methods: Parental (=sensitive) and docetaxel-resistant PCa cell lines, PC3, DU145, LNCaP, and 22Rv1 were exposed to SHI [0.1 - 1.5 μM] for 24, 48, or 72 hours. Untreated…

Cancer ResearchCell cycle checkpointbusiness.industryNecroptosisCancerCell cycleurologic and male genital diseasesmedicine.diseaseProstate cancerOncologyDocetaxelDU145LNCaPCancer researchMedicinebusinessmedicine.drugCancer Research
researchProduct

Extraprostatic Spindle Cell Stromal Tumor of the Prostate: Case Report

2007

Several benign and malignant nonepithelial and stromal-like lesions arise in the prostate. Because such lesions are rare, their recognition is essential, because treatment and prognosis depend on an adequate pathohistologic classification. We report a case of an 83-year-old man with a stromal tumor of the prostate of uncertain malignant potential (STUMP). He presented with urinary retention and rectal constipation. On bimanual examination, a rectally and suprapubically palpable mass was found. Imaging studies revealed a 12 x 8 cm pararectal inhomogeneous mass of uncertain origin compressing rectum and urethra. The tumor was resected by a retropubic approach and examined immunohistochemicall…

Aged 80 and overMalePathologymedicine.medical_specialtyConstipationUrinary retentionbusiness.industryUrologyCarcinomaCellProstatic NeoplasmsRectumExtraprostaticUrethramedicine.anatomical_structureProstateAbdominal NeoplasmsmedicineHumansmedicine.symptomStromal tumorbusinessUrology
researchProduct

Lifetime total and beverage specific - alcohol intake and prostate cancer risk: a case-control study

2004

Abstract Background We investigated lifetime alcohol consumption and prostate cancer risk in a case-control study conducted in Buffalo, NY (1998–2001). Methods The study included 88 men, aged 45 to 85 years with incident, histologically-confirmed prostate cancer and 272 controls. We conducted extensive in-person interviews regarding lifetime alcohol consumption and other epidemiologic data. Results Prostate cancer risk was not associated with lifetime intake of total and beverage specific ethanol. In addition we found no association with number of drinks per day (average drinks per day over the lifetime) or drinks per drinking day (average drinks per day on drinking days only over the lifet…

Prostate cancer riskNutrition and Dieteticsbusiness.industryCase-control studyMedicine (miscellaneous)Case Reportlcsh:TX341-641Clinical nutritionmedicine.disease3. Good health03 medical and health sciencesProstate cancerlcsh:Nutritional diseases. Deficiency diseases0302 clinical medicine030220 oncology & carcinogenesisEnvironmental healthEtiologyMedicineAlcohol intake030212 general & internal medicineEpidemiologic databusinessAlcohol consumptionlcsh:Nutrition. Foods and food supplylcsh:RC620-627Nutrition Journal
researchProduct

The Effects of Sodium Nitroprusside-Induced Hypotension on Splanchnic Perfusion and Hepatocellular Integrity

1999

UNLABELLED The purpose of our study was to investigate the effects of sodium nitroprusside-induced hypotension on splanchnic perfusion and hepatocellular integrity. Thirty patients undergoing radical prostatectomy were allocated randomly to a sodium nitroprusside (SNP) or control group (control). Regional pco2 was measured using gastric tonometry, and the regional to arterial difference in partial pressure of CO2 and intramucosal pH were calculated. The cytosolic liver enzyme alpha-glutathione S-transferase and standard liver enzyme markers (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyltransferase) were also measured. Mean arterial pressure in the SNP group was 50…

MaleNitroprussideMean arterial pressuremedicine.medical_specialtyPartial PressureVasodilator AgentsUrologyHemodynamicsBlood PressurepCO2medicineHumansSplanchnic CirculationGastric tonometryAntihypertensive AgentsGlutathione TransferaseProstatectomybusiness.industryLiver DiseasesCarbon DioxideMiddle AgedIsoenzymesOxygenAnesthesiology and Pain MedicineLiverAnesthesiaSodium nitroprussideLiver functionChemical and Drug Induced Liver InjuryHypotensionSplanchnicbusinessPerfusionBiomarkersmedicine.drugAnesthesia & Analgesia
researchProduct

SEX STEROID METABOLISM AND ACTION, INFLAMMATION AND PROSTATE CANCER: HYPOTHETICAL MECHANISMS AND NETWORKS

2012

Settore MED/04 - Patologia GeneraleSEX STEROID; PROSTATE CANCER;SEX STEROIDPROSTATE CANCER
researchProduct

An appraisal of telomerase activity in benign prostatic hyperplasia

2000

BACKGROUND Prostate cancer is one of the commonest neoplasms in elderly males in developed countries. It is not clear which individuals are at high risk of developing aggressive adenocarcinoma of the prostate. Biomarkers are therefore urgently needed to identify such individuals. It had been suggested both by ourselves and others that prostatic telomerase activity may represent a valuable marker in this respect, particularly if applied to BPH, as tissue is readily available from both transurethral resection of prostates and transrectal ultrasound biopsy. METHODS Tissue was collected prospectively from 46 patients with BPH who underwent TURP for clinically benign prostatic disease, and who w…

Pathologymedicine.medical_specialtyTelomeraseAdenomamedicine.diagnostic_testbusiness.industryUrologyUrologyCancerurologic and male genital diseasesmedicine.diseaseProstate cancermedicine.anatomical_structureOncologyProstateBiopsymedicineAdenocarcinomaProstate neoplasmbusinessThe Prostate
researchProduct

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

2016

<b><i>Purpose:</i></b> The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. <b><i>Methods:</i></b> Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m<sup>2</sup> every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The…

OncologyMalemedicine.medical_specialtyCancer Research030232 urology & nephrologyProstate neoplasmAntineoplastic AgentsDocetaxelCastration resistantAdenocarcinomaTaxaneSingle CenterAntineoplastic Agent03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineTaxoidmedicineClinical endpointHumansProspective StudiesAgedResponse rate (survey)GynecologyCabazitaxelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMetastatic castration-resistant prostate cancerProspective StudieProstatic Neoplasms Castration-ResistantDocetaxelOncologyCabazitaxel030220 oncology & carcinogenesisChemotherapy regimenDisease ProgressionPrednisoneTaxoidsbusinessmedicine.drugHuman
researchProduct

2017

AbstractInterleukin-4 plays a critical role in the regulation of immune responses and has been detected at high levels in the tumour microenvironment of cancer patients, where concentrations correlate with the grade of malignancy. In prostate cancer, interleukin-4 has been associated with activation of the androgen receptor, increased proliferation and activation of survival pathways such as Akt and NF-κB. However, its role in therapy resistance has not yet been determined. Here we investigate the influence of interleukin-4 on primary epithelial cells from prostate cancer patients. Our data demonstrate an increase in the clonogenic potential of these cells when cultured in the presence of i…

0301 basic medicineCancer Researchmedicine.medical_treatmentBiologymedicine.disease_causemedicine.disease3. Good health03 medical and health sciencesProstate cancer030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCytokineGrowth factor receptorProstate030220 oncology & carcinogenesisCancer researchmedicineStem cellCarcinogenesisClonogenic assayMolecular BiologyInterleukin 4Oncogenesis
researchProduct

Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

2019

Abstract Introduction The objective of the study was to determine the factors independently related with the development of castration resistance (CR) in prostate cancer (PC) in the medium term. Material and methods 155 patients diagnosed with metastatic PC with a follow-up of up to 39 months. Data taken from the National PC Registry. The evaluated variables were age, PSA, nadir PSA, Gleason, perineural invasion, TNM stages, and ADT type (intermittent / continuous). Results Mean follow-up 26,2 ± 13,4 months. 47.1% developed early CR, with mean time until onset of 12,2 ± 8,7 months. Univariate analysis: the mean PSA was correlated with CR (290 ± 905,1 ng/mL in non CR, 519,1 ± 1437,2 ng/mL in…

Oncologymedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industry030232 urology & nephrologyPerineural invasionGeneral Medicinemedicine.diseaseLower risk03 medical and health sciencesProstate cancer0302 clinical medicineCastration ResistanceInternal medicineTumor stagemedicinebusinessNadir (topography)Actas Urológicas Españolas (English Edition)
researchProduct